Pfenex is now set to start the process development activities with immediate action so as to offer materials to SAIC for ongoing pre-clinical studies.
The current contract is a result of successful pre-clinical studies performed utilizing the full length CSP antigen expressed in Pfenex Expression Technology.
CEO Bertrand Liang said they are pleased to be awarded this contract in support of DMID’s efforts to find an effective therapy for malaria.
"Pfenex Expression Technology has made the recombinant production of significant quantities of full length, soluble, active CSP antigen a reality, a complex protein that has previously been refractory to recombinant expression in other expression platforms" Liang said.